Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
56results about How to "Promote cell differentiation" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Methods and articles for regenerating bone or peridontal tissue
InactiveUS6409764B1Promote growth and developmentPromote cell differentiationDental implantsTeeth fillingPeriodontal tissueTransforming growth factor beta superfamily
There are numerous medical situations involving deficiencies of living bone or periodontal tissue and where increase of living bone or periodontal tissue mass is desired. Methods are described wherein a configured, shell-like device that is capable of being penetrated by living cells and tissues, is implanted into the body of a mammal in such a way as to establish a space, the space being at least partly, bounded by the device. The configuration of the device is such that the configuration of the established space is essentially the same as the configuration of living bone or periodontal tissue that is desired for treatment of the tissue deficiency. At least one protein from the Transforming Growth Factor-Beta Superfamily of proteins is placed within the established space for the purpose of stimulating the growth of living bone or periodontal tissue within the established space. A kit for the generation of living bone or periodontal tissue, comprised of the components mentioned above, is also disclosed.
Owner:WL GORE & ASSOC INC
Methods and reagents for the treatment of metabolic disorders
InactiveUS20060069161A1Reduced glucose levelHigh expressionOrganic active ingredientsSenses disorderDiabetes mellitusObesity
The invention features compositions, methods, and kits for the treatment of metabolic disorders such as diabetes and obesity.
Owner:ZALICUS INC
Differentiation of pluripotent cells
ActiveUS8372642B2Promote differentiationPromote cell differentiationNervous disorderCulture processBiologyBone marrow
Provided herein are methods for the in vitro maintenance, expansion, culture, and / or differentiation of pluripotent cells, such as human embryonic stem cells (hESC) or induced pluripotent cells (iPSC), into hematopoietic precursor cells or endothelial cells. The pluripotent cells may be maintained and differentiated under defined conditions; thus, the use of mouse feeder cells or serum is not required in certain embodiments for the differentiation of the pluripotent cells into hematopoietic precursor cells or endothelial cells. The resulting hematopoietic precursor cells may be further differentiated into various myeloid or lymphoid lineages.
Owner:FUJIFILM CELLULAR DYNAMICS INC
Elastin producing fibroblast formulations and methods of using the same
ActiveUS20080050346A1Good lookingStimulates elastogenesisBiocideCosmetic preparationsCell-Extracellular MatrixMedicine
The present invention describes therapeutic compositions comprising fibroblasts that have been stimulated to increase expression of extracellular matrix components or elastin, or to produce enhanced elastogenesis or the appearance thereof at a site of administration. The therapeutic fibroblast formulations can be prepared using a variety of elastogenic agents, including digests of mammalian elastin, chemically digested plant extracts comprising elastin-like peptides, and synthetic elastogenic peptides. The invention further comprises cosmetic and pharmaceutical treatment methods using the therapeutic fibroblast compositions of the invention.
Owner:ELASTOGENESIS LLC +1
Cardiac muscle function and manipulation
InactiveUS20060199767A1Promote cell differentiationImprove heart functionPeptide/protein ingredientsAntipyreticNeuregulinCardiomyocyte growth
Owner:ZENSUN (SHANGHAI) SCI & TECH CO LTD
Selection and propagation of progenitor cells
InactiveUS20060121605A1Inhibition of differentiationPromote and sustain growthBiocideMetabolism disorderProgenitorRegenerative medicine
The invention relates to a population of progenitor cells and methods for obtaining and culturing the progenitor cells. Methods and compositions of the present invention can be useful in fields including regenerative medicine (tissue regeneration), transplantation, and cancer research.
Owner:ORGAN RECOVERY SYST
Methods of treating tissue defects
InactiveUS20070105769A1Promote healingHigh expressionElectrotherapyPeptide/protein ingredientsTissue defectIntervertebral disk
Methods of treating tissue defects, including defects such as bone fractures, vertebrae fusions, and spinal disc repair, using electric or electromagnetic fields and growth factors. In various embodiments, the present invention provides methods for the treatment of a human or other mammal subject in need thereof, by administering electric stimulation and growth factors to stimulate endogeneous stem cells in the subject to facilitate healing. Other embodiments include methods of administering electric stimulation, growth factors, and stem cells to the defect. In various embodiments the amount of growth factor is a subefficacious amount.
Owner:EUROPEAN BIOINFORMATICS INSTITUTE
Production of Differentiated Enteroendocrine Cells and Insulin Producing Cells
ActiveUS20170349884A1Promote cell differentiationHigh expressionGastrointestinal cellsAntipyreticHistone methylationWnt inhibitor
A population of enteroendocrine cells (EEC) is obtained from a mammalian post-natal cell population, such as a population including post-natal stem cells, by treating the population with a plurality of small molecules that upregulate ChgA and promote differentiation of the cells to form the enteroendocrine cells. The upregulation of ChgA is such that the fraction of cells expressing CGA in the obtained cell population, as measured by a ChgA Immunostaining Assay, is at least about 1.5%. Small molecules that can be used to differentiate the post-natal cells into the enteroendocrine cells can include at least one of a Wnt activator, a Notch inhibitor, a Wnt inhibitor, a MEK / ERK inhibitor, a growth factor, a HDAC inhibitor, a Histone Methylation Inhibitor, a Tgf-β inhibitor, and a NeuroD1 activator. Also, the insulin expression of a population of mammalian cells is increased by treating the population with a plurality of small molecules that increase the insulin expression.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC +1
Tracers and assembly for labeling chemical or biological molecules methods and kits using the same
InactiveUS20110172110A1Simple trackPromote cell differentiationSequential/parallel process reactionsLibrary screeningEngineeringSilicon
An improved process to create an arbitrarily large number of distinguishable particles allows more flexibility in experimental design and related efficiencies of scale. Novel enhanced tracers, for example, Shape Encoded Particles (SEP's) function as indicator means, such as probe-carriers in massively multiplexed assays. Shape encoded identity provides an elegantly simple tracking mechanism, whereby binding / reaction probes coupled to SEP's surfaces can be monitored, viewed, imaged or otherwise utilized leveraging off of the generation of millions of distinct, for example, approximately 100×100×10 micron squared silicon flakes fabricated using conventional MEMS techniques. Plethoric related applications, and contemplated strategies for benefiting from the novel enhanced SEP's and their respective enabling technologies are disclosed, ranging from pearl cultering seed elements to uniquely identify resulting jewelry pieces to an improved parallel stem cell differentiation screening assays.
Owner:NOKIA SIEMENS NETWORKS GMBH & CO KG +2
Cornea edge stem cell tissue engineering composite body and its preparation method
InactiveCN1590541APromote cell differentiationPromote differentiationArtificially induced pluripotent cellsNon-embryonic pluripotent stem cellsBiological tissueLimbal stem cell
A tissue-engineered complex of human limbus stem cell and amnion for treating the limbus stem cell-deficiency eye diseases is disclosed. It is perpared through removing epithelium from amnion, using it as carrier, using fibroblast 3T3 as nutritive layer, culturing by cell suspension method, and promoting differentiation of cells by air-lifting technique.
Owner:天津医科大学眼科中心
Method of growing stem cells on a membrane containing projections and grooves
InactiveUS7695967B1Promote cell adhesionPromote cell differentiationBiocideDiagnosticsMechanobiologyBiochemistry
Owner:THE BOARD OF TRUSTEES OF THE UNIV OF ILLINOIS
Mesp1 as a master regulator of multipotent cardiovascular progenitor specification and uses thereof
InactiveUS20100330044A1Good specificationEfficient power generationBiocideSkeletal/connective tissue cellsProgenitorClinical settings
A method for differentiating or promoting or inducing differentiation of stem cells into pluripotent cardiovascular progenitors (MCPs) by transiently inducing the expression of a single gene, namely Mesp1, is disclosed. Cells obtained by the method and their uses in research and clinical settings are also disclosed. Using genome wide transcriptional analysis, the inventors found that Mesp1 rapidly activates and represses a discrete set of genes, which form potential new targets for both therapy and for the identification of MCPs. Insights into the molecular mechanisms underlying the earliest step of cardiovascular specification and potential methods for dramatically increasing the number of cardiovascular cells for cellular therapy in humans are provided.
Owner:UNIV LIBRE DE BRUXELIES
Methods and compositions for increasing neurogenesis and angiogenesis
PendingUS20160220640A1Increase neurogenesisImprove the level ofNervous disorderPeptide/protein ingredientsProgenitorNeurogenesis
Methods and compositions for rejuvenating neural stem cells and / or progenitor cells, increasing neurogenesis, increasing angiogenesis, and treating or preventing neurodegenerative and neurovascular disorders are disclosed.
Owner:THE BRIGHAM & WOMENS HOSPITAL INC +1
Methods for improving conifer embryogenesis
InactiveUS6893873B2High frequencyPromote cell differentiationTissue cultureHorticulture methodsOrganic acidSomatic embryogenesis
The present invention provides methods for initiating, capturing, maintaining and multiplying embryogenic cultures of coniferous plants. Methods include the use of novel media compositions containing Vitamin B12, Vitamin E, or organic acids including α-ketoglutaric acid, pyruvic acid, or p-aminobenzoic acid to improve the frequency of embryogenic tissue initiation, capture, maintenance and multiplication. The methods are well suited for initiating embryogenic cultures in recalcitrant conifer varieties. The method is also well suited for producing somatic embryos that can be further cultured to produce large numbers of plants. Further, the invention provides novel methods that may be used to enhance somatic embryogenesis in a broad range of species.
Owner:GEORGIA TECH RES CORP
Amino terminal substance P compositions and methods for using the same
InactiveUS7119071B2Reduce inflammationGood effectNervous disorderTetrapeptide ingredientsProgenitorCancer therapy
The present invention establishes the fact that the degradation of SP to SP(1-4) by endogenous NEP in BM stroma can be a mediator of hematopoietic stimulation by stem cell factor (SCF) and induce the production of TGF-β and TNF-α in BM stroma. The present invention establishes that compositions containing the SP(1-4) polypeptide, or NEP genetic elements, can be used to slow and or stop the rapid growth of stem and progenitor cells thus protecting them from the deleterious effects of cancer therapy. Hence, the polynucleotides and proteins of the present invention may be used to protect stem cells from the toxic effects of chemo- and radio-therapy, in those undergoing, or about to undergo such cancer related treatments. Also provided are compositions containing NEP antisense sequences and antibodies used for the increased proliferation and differentiation of stem and / or progenitor cells in those whom have already undergone chemo- and / or radio-therapy.
Owner:NEW JERSEY UNIVESITY OF MEDICINE & DENTISTRY OF
Method and systems for forming and using nanoengineered sculptured thin films
InactiveUS20070148206A1Promote cell differentiationPromote proliferationSurgeryPharmaceutical containersNanometreMonomer
A method of forming a sculptured thin film on a surface includes rotating the surface and depositing a sculptured thin film comprised of a polymer on the surface to form submicron wires during the step of rotating. The submicron wires may be columnar, helically columnar, chevron shaped, chiral shaped, distinct or interwoven. The depositing step may involve pyrolizing the polymer into a vapor of monomers, directing the vapor of monomers towards the surface while rotating the surface, and polymerizing the monomers on the surface. The surface may be incorporated into biomedical device or other biological application where the sculptured thin film is biocompatible and bioactive and adapted for a biological use.
Owner:PENN STATE RES FOUND
Oligodendrocyte determination genes and uses thereof
ActiveUS20070025975A1Promote cell differentiationIncrease differentiationBiocideGenetically modified cellsDiseaseOligodendrocyte differentiation
The invention relates to methods and reagents for promoting the differentiation of oligodendrocytes from stem cells, by co-activating the Olig genes and the Nkx2.2 genes, and the use of the differentiated oligodendrocytes thus obtained in treating diseases, such as Multiple Sclerosis (MS). The invention also relates to the use of OLPs and oligodendrocytes thus obtained for drug screening.
Owner:CALIFORNIA INST OF TECH
Method to amplify cardiac stem cells in vitro and in vivo
ActiveUS20100260727A1Facilitated DiffusionImprove scalabilityBiocideImmunoglobulins against cytokines/lymphokines/interferonsIn vivoCardiac Stem Cell
Compositions comprising stem cells delivered into infarcted myocardium by endocardial injection, engraft and differentiate into myocytes, endothelial cells, and vascular smooth muscle, and do so without the requirement for survival enhancing modification. These cells engraft whether injected acutely (days) or late (months) after myocardial infarction, and the efficiency of engraftment correlates with the functional recovery of the heart. The stem cells also recruit endogenous cardiac precursor cells, reconstitute myocardial stem cell niches, and enhance endogenous cell differentiation into myocytes.
Owner:VESTION
Medical material and method for manufacturing same
ActiveUS20130266620A1High biocompatibilityPromote differentiation of cellOrganic active ingredientsElectric discharge heatingLysine residueTryptophan
The present invention aims to provide a medical material which is safe for the live body, has high biocompatibility and is useful for promotion of cell differentiation. The present invention produces a medical material for promoting cell differentiation, which contains polyamino acid as a main component, wherein the polyamino acid contains at least one kind of amino acid residue selected from the group consisting of an alanine residue, a valine residue, a leucine residue, an isoleucine residue, a phenylalanine residue, a glycine residue, a glutamine residue, an aspartic acid residue optionally containing a protecting group in the side chain, a tyrosine residue optionally containing a protecting group in the side chain, a tryptophan residue optionally containing a protecting group in the side chain, a lysine residue optionally containing a protecting group in the side chain, and a glutamic acid residue optionally containing a protecting group in the side chain.
Owner:AJINOMOTO CO INC
Elastin producing fibroblast formulations and methods of using the same
ActiveUS7803522B2Good lookingStimulates elastogenesisBiocideCosmetic preparationsCell-Extracellular MatrixFibroblast
The present invention describes therapeutic compositions comprising fibroblasts that have been stimulated to increase expression of extracellular matrix components or elastin, or to produce enhanced elastogenesis or the appearance thereof at a site of administration. The therapeutic fibroblast formulations can be prepared using a variety of elastogenic agents, including digests of mammalian elastin, chemically digested plant extracts comprising elastin-like peptides, and synthetic elastogenic peptides. The invention further comprises cosmetic and pharmaceutical treatment methods using the therapeutic fibroblast compositions of the invention.
Owner:ELASTOGENESIS LLC +1
Method for remyelinating a demyelinized lesion due to injury in the brain or spinal cord
InactiveUS7098027B2Prepared safely and readilyBeneficial in medical industryBone marrow stroma cellsBiocideMedicineBone marrow cell
Owner:MITSUI SUMITOMO INSURANCE CARE NETWORK CO LTD RECEIVES 5 +2
Adaptive SOL-GEL immobilization agents for cell delivery
The present invention relates to formulations which form hydrogels at physiological temperatures. More specifically, the present invention relations to formulations having a prepolymer, an additive, and a temperature protectant, wherein the prepolymer and additive polymerize at physiological conditions to form a hydrogel. The formulations can further comprise cell suspensions such that the formation of the hydrogel leads to encapsulation of the cells in the hydrogel. The cells can then be slowly released into the surrounding environment of the hydrogel, allowing for more effective cell delivery.
Owner:FLORIDA INT UNIV BOARD OF TRUSTEES
Generation of photoreceptors from human retinal progenitor cells using polycaprolactone substrates
InactiveUS20130189341A1Promote cell differentiationBiocideSenses disorderDiseaseRetinitis pigmentosa
The present invention relates to biocompatible compositions for transplantation into a sub-retinal space of the human eye. The compositions include a biodegradable polyester film, preferably a polycaprolactone (PCL) film, and a layer of human retinal progenitor cells. The compositions of the invention can be used as scaffolds for the treatment a number of ocular diseases, including retinitis pigmentosa and age-related macular degeneration.
Owner:THE SCHEPENS EYE RES INST
Hydrogel-forming composition comprising natural and synthetic segments
InactiveUS20120003176A1Promote tissue regenerationImprove cell adhesionBiocideSurgical adhesivesPolymer scienceUltimate tensile strength
A hydrogel composition is formed from a natural polymer derivative having a plurality of cross-linkable units depending therefrom, and a synthetic polymer derivative having a plurality of cross-linkable units depending therefrom, said natural and synthetic polymer derivatives having hydrolysable units disposed between the polymer backbone of said derivative and at least some of said cross-linkable units. The use of a combination of natural and synthetic polymers provides for biodegradability of the hydrogel, along with mechanical properties such as strength and elasticity.
Owner:ZIMMER ORTHOBIOLOGICS
Metallothionein-derived peptide fragments
ActiveUS8618060B2Promote cell differentiationGood effectAntibacterial agentsPeptide/protein ingredientsDiseaseNeural cell
Owner:UNIVERSITY OF TASMANIA
Method to amplify cardiac stem cells in vitro and in vivo
ActiveUS20140369976A1Improve scalabilityEliminate needBiocideMammal material medical ingredientsIn vivoCardiac Stem Cell
Compositions comprising stem cells delivered into infarcted myocardium by endocardial injection, engraft and differentiate into myocytes, endothelial cells, and vascular smooth muscle, and do so without the requirement for survival enhancing modification. These cells engraft whether injected acutely (days) or late (months) after myocardial infarction, and the efficiency of engraftment correlates with the functional recovery of the heart. The stem cells also recruit endogenous cardiac precursor cells, reconstitute myocardial stem cell niches, and enhance endogenous cell differentiation into myocytes.
Owner:VESTION
Fluorapatite glass-ceramics
InactiveUS20140271565A1Increase depositionPromote growthBiocideSurgical adhesivesMedicineGlass-ceramic
The present invention provides a highly-sintered fluorapatite glass-ceramic comprising a high Ca / Al or Sr / Al mole-ratio, that possesses a microstructure that induces apatite / bone deposition.
Owner:UNIV OF IOWA RES FOUND
Elastin producing fibroblast formulations and methods of using the same
ActiveUS20110081322A1Good lookingStimulates elastogenesisCosmetic preparationsOrganic active ingredientsCell-Extracellular MatrixMedicine
The present invention describes therapeutic compositions comprising fibroblasts that have been stimulated to increase expression of extracellular matrix components or elastin, or to produce enhanced elastogenesis or the appearance thereof at a site of administration. The therapeutic fibroblast formulations can be prepared using a variety of elastogenic agents, including digests of mammalian elastin, chemically digested plant extracts comprising elastin-like peptides, and synthetic elastogenic peptides. The invention further comprises cosmetic and pharmaceutical treatment methods using the therapeutic fibroblast compositions of the invention.
Owner:ELASTOGENESIS LLC +1
Metallothionein-Derived Peptide Fragments
ActiveUS20100166759A1Inhibit oxidative stressInhibit the inflammatory responseAntibacterial agentsPeptide/protein ingredientsNeural cellPharmaceutical drug
Owner:UNIVERSITY OF TASMANIA
Induction of Germ Cells from Pluripotent Cells
InactiveUS20120231451A1Promotes germ cell differentiationIncrease differentiationMicrobiological testing/measurementArtificial cell constructsPlant Germ CellsGerm cell
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com